Importance of heart failure duration for development of pulmonary hypertension in advanced heart failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,46 MB, PDF-dokument

  • Freja Pust
  • Tania Deis
  • Johan Larsson
  • Benjamin Lautrup Hansen
  • Kasper Rossing
  • Mads Ersbøll
  • Søren Lund Kristensen
  • Gustafsson, Finn
Background and objectives
Pulmonary vascular resistance (PVR) is critical when evaluating candidacy for advanced heart failure (HF) therapies, but risk factors for elevated PVR are not well studied. We hypothesized that HF duration would be associated with elevated PVR.

Methods
Danish single-center registry of consecutive in- and outpatients undergoing right heart catheterization as part of advanced HF work up. The relation between HF duration and PVR was estimated by regression analysis. Finally, the relation between PVR and long-term mortality was assessed by Cox proportional hazards regression and Kaplan-Meier analyses.

Results
A total of 549 patients (77% men, median age 54 (43–61) years, median HF duration 1.6 years (0.1–7.1)) were included. Univariate linear regression displayed an association between longer HF duration and increasing PVR (p = 0.014). PVR > 3 WU was present in 92 patients (17%) who were older (median p < 0.001) and had longer HF duration (p = 0.03). HF duration (per 1 year increase) did not predict PVR > 3 WU after adjustment for covariables (OR 1.00; p = 0.99). During a mean follow-up time of 4.5 years, there were 240 (44%) deaths. Increasing PVR was associated with elevated all-cause mortality risk (adjusted HR 1.24; p < 0.001). PVR > 3 WU was associated with higher mortality (adjusted HR 1.49; p = 0.027).

Conclusion
Longer duration of HF was associated with higher PVR in patients with advanced HF, but this association disappeared in multivariate analyses. Longer HF duration per se likely does not cause elevated PVR and should not discourage evaluation for heart transplantation.
OriginalsprogEngelsk
Artikelnummer131232
TidsskriftInternational Journal of Cardiology
Vol/bind391
Antal sider8
ISSN0167-5273
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This study was funded by Novo Nordisk Foundation Clinical Distinguished Investigator Grant ( NNF20OC0060561 ). Novo Nordisk Foundation , Tuborg Havnevej 19, 2900 Hellerup, Denmark.

Publisher Copyright:
© 2023 The Author(s)

ID: 374560937